Premier signs DES deal with Abbott, Johnson & Johnson
Premier, a U.S. hospital purchasing group, has signed new agreements for drug-eluting stents (DES) with Abbott Laboratories and Johnson & Johnson's Cordis. .

The group's 13-month agreements with the two stent makers became effective on Jan. 1. Premier said the agreements are available to its acute-care and continuum-of-care members.

Owned by non-profit hospitals, Premier runs a purchasing network that serves more than 2,100 U.S. hospitals and 53,000 other healthcare sites.

DES currently represent a roughly $2 billion market in the United States, according to Dow Jones.


Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup